Clinical Features and Outcomes of Patients With Diffuse Unilateral Subacute Neuroretinitis Treated With Oral Albendazole

To investigate the clinical features, visual function outcomes, and adverse events in patients with diffuse unilateral subacute neuroretinitis (DUSN) treated with high-dose oral albendazole. Interventional case series. Twelve Brazilian patients, aged 7 through 36 years, with active DUSN in the early...

Full description

Saved in:
Bibliographic Details
Published in:American journal of ophthalmology 2005-09, Vol.140 (3), p.437.e1-437.e11
Main Authors: Souza, Eduardo C., Casella, Antônio Marcelo B., Nakashima, Yoshitaka, Monteiro, Mário Luiz R.
Format: Article
Language:English
Subjects:
Acute Disease
Administration, Oral
Adolescent
Adult
Albendazole - administration & dosage
Albendazole - adverse effects
Anthelmintics - administration & dosage
Anthelmintics - adverse effects
Biological and medical sciences
Child
Drug dosages
Female
Glaucoma
Humans
Male
Medical research
Medical sciences
Miscellaneous
Nematodes
Ophthalmology
Retinitis - drug therapy
Retinitis - parasitology
Retinitis - physiopathology
Safety
Treatment Outcome
Tropical diseases
Visual Acuity - physiology
Visual Fields - physiology
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:To investigate the clinical features, visual function outcomes, and adverse events in patients with diffuse unilateral subacute neuroretinitis (DUSN) treated with high-dose oral albendazole. Interventional case series. Twelve Brazilian patients, aged 7 through 36 years, with active DUSN in the early or late clinical stage, were recruited for this study between 1999 and 2001. A small variant motile worm was found in 4 (33.3%) of these cases. All patients were treated exclusively with high-dose oral albendazole (400 mg/d) for 30 days. Improvement of visual acuity, visual field, and active ocular inflammatory signs was observed in all patients after 4 weeks of treatment (median follow-up: 3 years). Also, during the first weeks of treatment, evidence of worm inactivation was documented for the four patients with visible worms. No adverse drug side effects were observed in any of our cases during follow-up. High-dose oral albendazole seems to be safe and beneficial for patients with DUSN.
ISSN:0002-9394
1879-1891
DOI:10.1016/j.ajo.2005.03.065